Tag: biotech
-
WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Driving Sustainable High Growth in 2025
WuXi Biologics Advances with a Scaled CRDMO Platform The CRDMO (Contract Research, Development, and Manufacturing Organization) platform at WuXi Biologics is positioned for sustained high growth under the leadership of CEO Dr. Chris Chen. In 2025, the company reported a landmark achievement: a total of 945 integrated projects, including 74 Phase III clinical projects and…
-
Nine Tech Developments by 2050: The Future Forecast
Introduction: Gazing Toward 2050 Futurologists often spark lively debates about what the world will look like in 2050. The common thread across credible forecasts is not a single leap forward but a convergence of advances across artificial intelligence, biology, energy, and space. In this article, a leading futurologist outlines nine credible tech developments that could…
-
MIT’s Smart Pill: A Breakthrough in Verifying Medication Adherence
What is the MIT Smart Pill? Researchers at MIT have developed a smart pill technology that can confirm whether a patient has taken their medicine. The system is designed to be incorporated directly into existing pill capsules and uses a biodegradable radio frequency (RF) antenna to send a signal shortly after ingestion. This signal can…
-
Arkin Bio Ventures III: Arkin Capital launches a $100M fund for early clinical biotech
Arkin Capital doubles down on early clinical science Arkin Capital has unveiled Arkin Bio Ventures III, a new $100 million biotech fund dedicated to advancing early-stage clinical science. In a landscape that increasingly prizes AI-driven drug discovery, Arkin’s strategy centers on the highest-impact, patient-centered stages of development: the first-in-human and early clinical readouts that can…
-
SOPHiA GENETICS Reports 2025 Results, Sets 2026 Guidance, and Announces CEO Transition
Strong Q4 2025 Performance and Full-Year Results SOPHiA GENETICS, a global leader in AI-driven precision medicine, announced preliminary fourth-quarter and full-year 2025 financial results, highlighting robust momentum as the company advances its AI-powered platform across life sciences and clinical applications. While the company noted that the 2025 results are preliminary, management emphasized solid quarterly execution…
-
Arkin Bio Ventures III Raises $100M Biotech Fund for Early Clinical Science
Arkin Capital Expands Focus with $100 Million Biotech Fund Arkin Capital has announced the close of a new $100 million fund, Arkin Bio Ventures III, signaling a reinforced commitment to traditional, early-stage clinical science in biotechnology. While the biotech sector has been abuzz with artificial intelligence-driven drug discovery narratives, Arkin’s latest fund underscores a deliberate…
-
SOPHiA GENETICS Announces 2025 Results, 2026 Guidance, and CEO Transition Plan
Executive Summary: Strong 2025 Close and New Growth Outlook SOPHiA GENETICS (Nasdaq: SOPH) has disclosed preliminary fourth-quarter and full-year 2025 financial results, along with guidance for 2026 and a strategic executive transition. The company underscored a solid close to 2025, highlighted by robust Q4 performance, and introduced its 2026 revenue growth target of 20-22%. In…
-
Arkin Bio Ventures III: A $100M Bet on Early Clinical Biotech
Arkin Capital Bets on Early Clinical Biotech with a $100 Million Fund In a move that underscores a distinct approach within the crowded life sciences investment landscape, Arkin Capital has closed a new $100 million fund dedicated to early clinical science in biotechnology. The launch of Arkin Bio Ventures III marks a deliberate shift away…
-
Brain Organoids: A New Frontier in Brain Health Research
What Are Brain Organoids and Why They Matter Brain organoids are tiny, lab-grown clusters of neural tissue that resemble aspects of a developing human brain. Created from stem cells, these pea-sized structures can grow and mature over months, forming neural networks, synapses, and regional patterns that echo early brain development. Researchers use brain organoids to…
-
Tiger BioSciences Highlights 2025 Clinical Milestones After Bold Research Investment
Overview: A Year of Strategic Investment and Impact In 2025, Tiger BioSciences positioned itself at the forefront of evidence-based biotherapeutics, translating a significant investment in scientific research into tangible clinical milestones. The company’s renewed emphasis on rigorous preclinical validation, translational science, and disciplined trial design aimed to accelerate the journey from discovery to patient impact.…